| Pharmacology |
|
| Administration route | ORAL |
| Organism | Gastrodia elata (ORCHIDACEAE) |
| Citation | YU,SY: RAN,Y: XIAO,W: TANG,WJ: ZHAO,JJ: CHEN,W: ZHUANG,HK: OUYANG,C: LIN,H: LIU,DQ: CHEN,TJ: HUANG,H: WANG,BS: HAO,YL: YAN,ZR: ZHAO,S: WANG,YL: NI,JJ: WANG,CD: DING,WT: LI,GQ: CAO,JH:TIAN,SJ:. (2019). TREATMENT OF MIGRAINES WITH TIANSHU CAPSULE: A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL. 19() |
| Amount utilized | |
| Compound isolated | |
| Disease | DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL THAT CONDUCTED AT 20 CLINICAL CENTERS IN CHINA. AT ENROLLMENT, PATIENTS BETWEEN 18 AND 65 YEARS OF AGE DIAGNOSED WITH MIGRAINE WERE ASSIGNED
TO RECEIVE EITHER TSC (4.08 G, THREE TIMES DAILY) OR A MATCHED PLACEBO ACCORDING TO A RANDOMIZATION PROTOCOL. THE PRIMARY ENDPOINT WAS A RELATIVE REDUCTION OF 50% OR MORE IN THE FREQUENCY OF HEADACHE ATTACKS. THE SECONDARY
OUTCOMES INCLUDED A REDUCTION IN THE INCIDENCE OF HEADACHE, THE VISUAL ANALOGUE SCALE OF HEADACHE ATTACKS, DAYS OF ACUTE ANALGESIC USAGE, AND PERCENTAGE OF PATIENTS WITH A DECREASE OF 50% OR MORE IN HEADACHE SEVERITY. TSC IS AN EFFECTIVE, WELL-TOLERATED MEDICINE FOR PROPHYLACTIC TREATMENT OF MIGRAINE, AND STILL HAVE
PROPHYLACTIC EFFECT AFTER MEDICINE DISCONTINUATION. |
| Dose amount | 12 GM |
| Number | 1 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Per unit | DAY |
| Dose expression | DOSE |
| Extract | ETOH(95%)EXT |